![]() Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Severe hypersensitivity reaction to TRODELVY. ![]() If severe diarrhea occurs, withhold TRODELVY until resolved to ≤Grade 1 and reduce subsequent doses. At the onset of late diarrhea, evaluateįor infectious causes and, if negative, promptly initiate loperamide. Administer atropine, if not contraindicated, for early diarrhea of any severity. Monitor patients with diarrhea and give fluid and electrolytes as needed. Initiate anti-infective treatment in patients with febrile neutropenia without delay. Monitor blood cell counts periodically during treatment. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Severe or life-threatening neutropenia may occur. Please download the resource guide below to assist you with proper coding to help optimize reimbursement support. Gilead and its agents make no guarantee regarding reimbursement for any service or item.Ĭoverage, billing, and coding requirements for TRODELVY may vary by plan and patient. Its agents, will contact the patient directly regarding the application process. The foundation will determine the patient’s eligibility for co-pay or co-insurance assistance based on their own criteria and, completely independent of Gilead and Managers can provide information about any available foundations. ![]() If co-pay assistance needs are identified, the Case Case Managers can help patients assess their high-level eligibility for possible coverage for TRODELVY through an independent co-pay assistance foundation. ![]() ‡Patients with Medicare or other government insurance who need assistance with cost-share requirements for TRODELVY may be eligible for co-pay or co-insurance assistance through an independent co-payĪssistance foundation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |